Guilaine Boursier

2.0k total citations · 1 hit paper
50 papers, 551 citations indexed

About

Guilaine Boursier is a scholar working on Molecular Biology, Immunology and Physiology. According to data from OpenAlex, Guilaine Boursier has authored 50 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 21 papers in Immunology and 13 papers in Physiology. Recurrent topics in Guilaine Boursier's work include Inflammasome and immune disorders (18 papers), Clinical Laboratory Practices and Quality Control (9 papers) and IL-33, ST2, and ILC Pathways (8 papers). Guilaine Boursier is often cited by papers focused on Inflammasome and immune disorders (18 papers), Clinical Laboratory Practices and Quality Control (9 papers) and IL-33, ST2, and ILC Pathways (8 papers). Guilaine Boursier collaborates with scholars based in France, Netherlands and Spain. Guilaine Boursier's co-authors include Isabelle Touitou, Pika Meško Brguljan, Marc Thelen, Florent Vanstapel, Francisco A. Bernabéu-Andréu, Guillaume Sarrabay, Sophie Georgin‐Lavialle, Luděk Šprongl, Christos Κroupis and Michel Vaubourdolle and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Immunology and The Journal of Pediatrics.

In The Last Decade

Guilaine Boursier

42 papers receiving 542 citations

Hit Papers

Mechanisms of NLRP3 activation and inhibition elucidated ... 2025 2026 2025 5 10 15 20
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants
    2025 24 citations Shouya Feng, Katja Hrovat-Schaale et al. Nature Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guilaine Boursier France 14 193 151 127 63 62 50 551
Reza Jafarzadeh Esfehani Iran 14 214 1.1× 36 0.2× 60 0.5× 39 0.6× 123 2.0× 76 705
Mervyn R. Stein United States 6 55 0.3× 109 0.7× 160 1.3× 40 0.6× 42 0.7× 7 495
A Cohen Canada 9 135 0.7× 187 1.2× 25 0.2× 26 0.4× 92 1.5× 12 575
Rüdiger Vollandt Germany 14 152 0.8× 80 0.5× 171 1.3× 68 1.1× 237 3.8× 34 886
Zhengbo Tao China 12 202 1.0× 43 0.3× 38 0.3× 30 0.5× 58 0.9× 32 510
S.T. Shaw United States 16 68 0.4× 54 0.4× 126 1.0× 21 0.3× 76 1.2× 44 836
Thanitsara Rittiphairoj United States 12 105 0.5× 89 0.6× 14 0.1× 35 0.6× 39 0.6× 37 452
Y. Li China 16 104 0.5× 50 0.3× 79 0.6× 26 0.4× 357 5.8× 47 903
Marco Migliardi Italy 15 47 0.2× 39 0.3× 30 0.2× 63 1.0× 83 1.3× 40 576

Countries citing papers authored by Guilaine Boursier

Since Specialization
Citations

This map shows the geographic impact of Guilaine Boursier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guilaine Boursier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guilaine Boursier more than expected).

Fields of papers citing papers by Guilaine Boursier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guilaine Boursier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guilaine Boursier. The network helps show where Guilaine Boursier may publish in the future.

Co-authorship network of co-authors of Guilaine Boursier

This figure shows the co-authorship network connecting the top 25 collaborators of Guilaine Boursier. A scholar is included among the top collaborators of Guilaine Boursier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guilaine Boursier. Guilaine Boursier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feng, Shouya, Katja Hrovat-Schaale, Yaoyuan Zhang, et al.. (2025). Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants. Nature Immunology. 26(3). 511–523. 24 indexed citations breakdown →
2.
Bélot, Alexandre, Odile Boespflug‐Tanguy, Guilaine Boursier, et al.. (2025). French protocol for diagnosis and management of type 1 interferonopathies. La Revue de Médecine Interne. 46(6). 320–340.
3.
Bélot, Alexandre, et al.. (2025). How (Ultra‐)Rare Gene Variants Improve Our Understanding of More Common Autoimmune and Inflammatory Diseases. ACR Open Rheumatology. 7(2). e70003–e70003. 2 indexed citations
4.
Linko, Solveig, Guilaine Boursier, Francisco A. Bernabéu-Andréu, et al.. (2025). EN ISO 15189 revision: EFLM Committee Accreditation and ISO/CEN standards (C: A/ISO) analysis and general remarks on the changes. Clinical Chemistry and Laboratory Medicine (CCLM). 63(6). 1084–1098. 1 indexed citations
5.
Çubukçu, Hikmet Can, Guilaine Boursier, Solveig Linko, et al.. (2025). Regulating the future of laboratory medicine: European regulatory landscape of AI-driven medical device software in laboratory medicine. Clinical Chemistry and Laboratory Medicine (CCLM). 63(10). 1891–1914. 1 indexed citations
6.
Brguljan, Pika Meško, Marc Thelen, Francisco A. Bernabéu-Andréu, et al.. (2024). EFLM Working Group Accreditation and ISO/CEN standards on dealing with ISO 15189 demands for retention of documents and examination objects. SHILAP Revista de lepidopterología. 5(2). 103–108. 2 indexed citations
7.
Mertz, Philippe, Véronique Hentgen, Guilaine Boursier, Jérôme Delon, & Sophie Georgin‐Lavialle. (2023). Revue de la littérature sur les syndromes auto-inflammatoires monogéniques liés aux actinopathies. La Revue de Médecine Interne. 44(11). 585–593. 1 indexed citations
8.
Aouba, Achille, Quentin Riller, Guilaine Boursier, et al.. (2023). L’haploinsuffisance de A20 : que doit connaître le clinicien?. La Revue de Médecine Interne. 45(7). 415–422.
9.
Vasseneix, Caroline, et al.. (2023). ROSAH syndrome: childhood-onset arthritis, hand deformities, uveitis, and splenomegaly. The Lancet Rheumatology. 5(9). e564–e564. 5 indexed citations
10.
Çubukçu, Hikmet Can, Florent Vanstapel, Marc Thelen, et al.. (2023). APS calculator: a data-driven tool for setting outcome-based analytical performance specifications for measurement uncertainty using specific clinical requirements and population data. Clinical Chemistry and Laboratory Medicine (CCLM). 62(4). 597–607. 12 indexed citations
11.
Vanstapel, Florent, Matthias Orth, Thomas Streichert, et al.. (2023). ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation. Clinical Chemistry and Laboratory Medicine (CCLM). 61(4). 608–626. 23 indexed citations
12.
Magnotti, Flora, Amandine Martin, Michel R. Popoff, et al.. (2023). Mutations in the B30.2 and the central helical scaffold domains of pyrin differentially affect inflammasome activation. Cell Death and Disease. 14(3). 213–213. 9 indexed citations
13.
Gangloff, Yann‐Gaël, Guilaine Boursier, C. Deligny, et al.. (2023). H syndrome mimicking Erdheim Chester disease: new entity and therapeutic perspectives. Haematologica. 108(8). 2255–2260. 3 indexed citations
14.
Lantman, Marith van Schrojenstein, Hikmet Can Çubukçu, Guilaine Boursier, et al.. (2022). An approach for determining allowable between reagent lot variation. Clinical Chemistry and Laboratory Medicine (CCLM). 60(5). 681–688. 21 indexed citations
15.
Rodrigues, François, Laurence Cuisset, Irina Giurgea, et al.. (2022). AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. Lara D. Veeken. 61(12). 4827–4834. 10 indexed citations
16.
Çubukçu, Hikmet Can, Florent Vanstapel, Marc Thelen, et al.. (2021). Improving the laboratory result release process in the light of ISO 15189:2012 standard. Clinica Chimica Acta. 522. 167–173. 11 indexed citations
17.
Brouillet, Sophie, et al.. (2020). C-reactive protein and ART outcomes: a systematic review. Human Reproduction Update. 26(5). 753–773. 18 indexed citations
18.
Wielders, Jos P.M., Guilaine Boursier, Florent Vanstapel, et al.. (2019). Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation. Clinical Chemistry and Laboratory Medicine (CCLM). 58(3). 361–367. 11 indexed citations
19.
Boursier, Guilaine, Cécile Rittore, Sophie Georgin‐Lavialle, et al.. (2019). Positive Impact of Expert Reference Center Validation on Performance of Next-Generation Sequencing for Genetic Diagnosis of Autoinflammatory Diseases. Journal of Clinical Medicine. 8(10). 1729–1729. 9 indexed citations
20.
Thelen, Marc, Florent Vanstapel, Pika Meško Brguljan, et al.. (2018). Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element. Clinical Chemistry and Laboratory Medicine (CCLM). 57(4). 459–464. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reza Jafarzadeh Esfehani Breakdown of academic impact, for papers by Mervyn R. Stein Breakdown of academic impact, for papers by A Cohen Breakdown of academic impact, for papers by Rüdiger Vollandt Breakdown of academic impact, for papers by Zhengbo Tao Breakdown of academic impact, for papers by S.T. Shaw Breakdown of academic impact, for papers by Thanitsara Rittiphairoj Breakdown of academic impact, for papers by Y. Li Breakdown of academic impact, for papers by Marco Migliardi
Rankless by CCL
2026